(Q34046863)

30 July 2017

1 reference

title

Costimulatory wars: the tumor menace (English)

1 reference

30 July 2017

A A Hurwitz

1

1 reference

30 July 2017

E D Kwon

series ordinal

2

1 reference

30 July 2017

A van Elsas

series ordinal

3

1 reference

30 July 2017

language of work or name

1 reference

1 October 2000

1 reference

30 July 2017

8

1 reference

Current Opinion in Immunology

inferred from page(s)

published in

1 reference

30 July 2017

12

1 reference

30 July 2017

5

1 reference

30 July 2017

589-596

1 reference

A Theory of Self-Nonself Discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

T cell co-stimulatory molecules other than CD28.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Costimulatory regulation of T cell function.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CTLA-4 can function as a negative regulator of T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Protective immunity to nematode infection is induced by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CTLA-4 is required for the induction of high dose oral tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Manipulation of costimulatory signals to enhance antitumor T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

A reassessment of the role of B7-1 expression in tumor rejection.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Enhancement of the anti-tumor immune response using a combination of interferon-gamma and B7 expression in an experimental mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Enhancement of antitumor immunity by CTLA-4 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Tumor immunity and autoimmunity induced by immunization with homologous DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Inducing autoimmune disease to treat cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

The OX-40 receptor provides a potent co-stimulatory signal capable of inducing encephalitogenicity in myelin-specific CD4+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Role of OX40 signals in coordinating CD4 T cell selection, migration, and cytokine differentiation in T helper (Th)1 and Th2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Engagement of the OX-40 receptor in vivo enhances antitumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: synergy with the CD28 co-stimulatory pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Antitumor responses induced by transgenic expression of CD40 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

The TRAIL to selective tumor death

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

LIGHT, a novel ligand for lymphotoxin beta receptor and TR2/HVEM induces apoptosis and suppresses in vivo tumor formation via gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

T-cell co-stimulation through B7RP-1 and ICOS

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CD4+ T cell help impairs CD8+ T cell deletion induced by cross-presentation of self-antigens and favors autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900147-3

7 January 2021

10.1016/S0952-7915(00)00147-3

Identifiers

DOI

1 reference

30 July 2017

1 reference